Search Results

There are 9650 results for: content related to: Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer

  1. Trastuzumab-containing regimens for metastatic breast cancer

    Intervention Review

    The Cochrane Library

    Sara Balduzzi, Stefania Mantarro, Valentina Guarneri, Ludovica Tagliabue, Vanna Pistotti, Lorenzo Moja and Roberto D'Amico

    Published Online : 12 JUN 2014, DOI: 10.1002/14651858.CD006242.pub2

  2. Trastuzumab containing regimens for early breast cancer

    Intervention Review

    The Cochrane Library

    Lorenzo Moja, Ludovica Tagliabue, Sara Balduzzi, Elena Parmelli, Vanna Pistotti, Valentina Guarneri and Roberto D'Amico

    Published Online : 18 APR 2012, DOI: 10.1002/14651858.CD006243.pub2

  3. You have free access to this content
    Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

    Cancer

    Volume 116, Issue 12, 15 June 2010, Pages: 2856–2867, Helena R. Chang

    Article first published online : 1 APR 2010, DOI: 10.1002/cncr.25120

  4. Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer

    The Journal of Clinical Pharmacology

    Volume 53, Issue 2, February 2013, Pages: 192–201, Chris Wynne, Vernon Harvey, Christian Schwabe, Devonie Waaka, Christine McIntyre and Beate Bittner

    Article first published online : 22 FEB 2013, DOI: 10.1177/0091270012436560

  5. You have free access to this content
    Biomarkers of drugs targeting HER-family signalling in cancer

    The Journal of Pathology

    Volume 232, Issue 2, January 2014, Pages: 219–229, Filippo Montemurro and Maurizio Scaltriti

    Article first published online : 10 DEC 2013, DOI: 10.1002/path.4269

  6. You have free access to this content
    Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer

    Cancer

    Volume 118, Issue 8, 15 April 2012, Pages: 1982–1988, Ana P. Kiess, Heather L. McArthur, Kathleen Mahoney, Sujata Patil, Patrick G. Morris, Alice Ho, Clifford A. Hudis and Beryl McCormick

    Article first published online : 1 SEP 2011, DOI: 10.1002/cncr.26484

  7. Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

    Cancer

    Amelia B. Zelnak and Kari B. Wisinski

    Article first published online : 23 JUL 2014, DOI: 10.1002/cncr.28815

  8. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 3, March 2013, Pages: 794–812, Zephania W. Kwong Glover, Lynn Gennaro, Sandeep Yadav, Barthélemy Demeule, Pin Yee Wong and Alavattam Sreedhara

    Article first published online : 5 DEC 2012, DOI: 10.1002/jps.23403

  9. You have full text access to this Open Access content
    Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

    Cancer Science

    Volume 102, Issue 1, January 2011, Pages: 1–8, Toru Mukohara

    Article first published online : 6 SEP 2010, DOI: 10.1111/j.1349-7006.2010.01711.x

  10. You have free access to this content
    Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S4, June 2014, Pages: 15–25, Richard De Boer, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence Francis, Michael Green, Ken Pittman, Michelle White, Nicholas Wilcken, Nicholas Zdenkowski and Richard Bell

    Article first published online : 6 MAY 2014, DOI: 10.1111/ajco.12207

  11. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait

    Asia-Pacific Journal of Clinical Oncology

    Yamini Krishnan, Shafika Al Awadi, P.S Sreedharan, Susovana Sujith Nair and Sanjay Thuruthel

    Article first published online : 12 AUG 2013, DOI: 10.1111/ajco.12118

  12. You have free access to this content
    Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network

    Cancer

    Volume 119, Issue 4, 15 February 2013, Pages: 839–846, Rachel A. Freedman, Melissa E. Hughes, Rebecca A. Ottesen, Jane C. Weeks, Yulei He, Yu-Ning Wong, Richard Theriault and Nancy L. Keating

    Article first published online : 25 SEP 2012, DOI: 10.1002/cncr.27831

  13. You have free access to this content
    Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response

    International Journal of Cancer

    Volume 131, Issue 10, 15 November 2012, Pages: 2420–2432, Sucheta Kulkarni, Leya Saju, Carol Farver and Raymond Tubbs

    Article first published online : 28 MAR 2012, DOI: 10.1002/ijc.27510

  14. You have free access to this content
    Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

    Cancer

    Volume 118, Issue 10, 15 May 2012, Pages: 2603–2614, Eun-Jung Jung, Libero Santarpia, Juyeon Kim, Francisco J. Esteva, Erica Moretti, Aman U. Buzdar, Angelo Di Leo, Xiao-Feng Le, Robert C. Bast Jr, Soon-Tae Park, Lajos Pusztai and George A. Calin

    Article first published online : 5 OCT 2011, DOI: 10.1002/cncr.26565

  15. Primary trastuzumab resistance: new tricks for an old drug

    Annals of the New York Academy of Sciences

    Volume 1210, Issue 1, October 2010, Pages: 53–65, Jason A. Wilken and Nita J. Maihle

    Article first published online : 25 OCT 2010, DOI: 10.1111/j.1749-6632.2010.05782.x

  16. You have free access to this content
    Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer

    Cancer

    Volume 118, Issue 20, 15 October 2012, Pages: 4936–4943, Michelle M. Kim, Shaheenah Dawood, Pamela Allen, Aysegul A. Sahin, Wendy A. Woodward, Benjamin D. Smith, Eric A. Strom, Kelly K. Hunt, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo and Thomas A. Buchholz

    Article first published online : 17 APR 2012, DOI: 10.1002/cncr.27502

  17. You have free access to this content
    Current and emerging targeted therapies for metastatic breast cancer

    Cancer

    Volume 118, Issue 12, 15 June 2012, Pages: 3014–3025, Edith A. Perez and Jean-Philippe Spano

    Article first published online : 17 OCT 2011, DOI: 10.1002/cncr.26356

  18. Trastuzumab (Herceptin) A Treatment for HER2-Positive Breast Cancer

    Handbook of Therapeutic Antibodies

    Stefan Dübel, Pages: 1109–1130, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch40

  19. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

    Cancer

    Volume 120, Issue 13, 1 July 2014, Pages: 1932–1938, Rashmi K. Murthy, Ankur Varma, Priyankana Mishra, Kenneth R. Hess, Elliana Young, James L. Murray, Kimberly H. Koenig, Stacy L. Moulder, Amal Melhem-Bertrandt, Sharon H. Giordano, Daniel Booser, Vicente Valero, Gabriel N. Hortobagyi and Francisco J. Esteva

    Article first published online : 26 MAR 2014, DOI: 10.1002/cncr.28689

  20. You have free access to this content
    Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: Local stimulation using magnetic microspheres as assessed by quantitative digital microscopy

    Cytometry Part A

    Volume 67A, Issue 2, October 2005, Pages: 161–171, Elza Friedländer, Donna J. Arndt-Jovin, Péter Nagy, Thomas M. Jovin, János Szöllősi and György Vereb

    Article first published online : 14 SEP 2005, DOI: 10.1002/cyto.a.20173